The Forschungszentrum Karlsruhe Expands DPN Facility by Adding NanoInk NLP 2000 Nanofabrication Platform
News Sep 09, 2009
Having been the first European facility to use NanoInk’s Dip Pen Nanolithography® (DPN®) technology in 2005, the Forschungszentrum Karlsruhe (FZK), has recently taken delivery of the first of two new systems to meet the increased user demand.
Located in the Nanomechanics Group of Professor Harald Fuchs, DPN is being used to drive practical applications in the fields of drug discovery, tissue engineering and the early detection of specific diseases. The Centre now offers open access to these instruments through the Karlsruhe NanoMicro Facility (KNMF).
The FZK has developed methods applying DPN for patterning with biological membrane lipids. Phospholipids are important biological molecules that self-assemble under physiological conditions to form the bilayer structure of biological membranes. However, available methods for generating phospholipid arrays on surfaces are severely limited in their lateral resolution. Based on non-covalent adhesion and humidity control of the liquid crystalline phase of the ink, it is possible to use phospholipids as a universal ink for DPN on a variety of substrates. Being able to produce 3D liposome-like structures on a surface allows model cells and membranes to be constructed.
Taken further, DPN’s multiplexing writing with different inks has provided the concept from which combinatorial nanostructure libraries of materials have been successfully developed.
The original platform for DPN was based on an atomic force microscope (AFM). However, for biological experiments, a rapid scale-up system is required to generate hundreds if not thousands of samples for testing to provide the required statistical approach of the biologist. A high powered imaging system was no longer required. This has driven the development of the NanoInk NLP 2000 nanofabrication platform to provide an easy-to-use system with a vastly increased speed of output for the generation of huge phospholipid arrays.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE